Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 13/20 | 0.49 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | NAE1 | Q13564 | 3/20 | 0.37 |
| ▸ | UBA3 | Q8TBC4 | 2/20 | 0.37 |
| ▸ | UBA1 | P22314 | 1/20 | 0.37 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.37 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4865176 | 1.00 | ADK (0.49) | ADKDOT1LADORA2ANPC1GALR3 | |
| SCHEMBL14111439 | 1.00 | ADK (0.49) | ADKDOT1LADORA2ANPC1GALR3 | |
| SCHEMBL14111736 | 1.00 | ADK (0.49) | ADKDOT1LADORA2ANPC1GALR3 | |
| SCHEMBL14111558 | 0.90 | ADK (0.49) | ADKDOT1LADORA2ANPC1GALR3 | |
| SCHEMBL14111740 | 0.90 | ADK (0.48) | ADKDOT1LADORA2ANPC1GALR3 | |
| SCHEMBL14453126 | 0.89 | ADORA2A (0.59) | ADKDOT1LADORA2ANPC1GALR3 | |
| SCHEMBL14598182 | 0.89 | ADORA2A (0.59) | ADKDOT1LADORA2ANPC1GALR3 | |
| SCHEMBL5319713 | 0.89 | ADORA2A (0.59) | ADKDOT1LADORA2ANPC1GALR3 | |
| SCHEMBL14453221 | 0.89 | ADORA2A (0.59) | ADKDOT1LADORA2ANPC1GALR3 | |
| SCHEMBL14111491 | 0.89 | ADK (0.49) | ADKDOT1LADORA2ANPC1GALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405204-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20060241064-A1 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241064-A1 | Nucleoside compounds for treating viral infections | PNP, HAVCR2, SAMHD1 | ADK 190/4885DOT1L 2129/4885ADORA2A 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.